Printer Friendly

Hyperion Therapeutics Inc swings to GAAP net income of USD0.1m in Q3 2013.

M2 EQUITYBITES-November 13, 2013-Hyperion Therapeutics Inc swings to GAAP net income of USD0.1m in Q3 2013(C)2013 M2 COMMUNICATIONS

Biopharmaceutical company Hyperion Therapeutics Inc (NasdaqGM:HPTX) on Tuesday declared a GAAP net income of USD0.1m (USD0.01 earnings per diluted share) for the Q3 2013.

This marks an improvement in earnings when compared with a net loss of USD4.9m (USD0.44 loss per diluted share) for the same period of 2012.

Net product revenue of USD15.5m was collected from the sale of RAVICTI and BUPHENYL for the third quarter of 2013.

The company added the net product revenue for the Q3 2013 period included USD9.8m in net sales from RAVICTI, up 58% from Q2 2013 RAVICTI sales of USD6.2m and USD6.0m in net sales from BUPHENYL.

Adjusted R&D expenses of USD2.3m was recorded for the three month periods ended 30 September 32013 and 2012, respectively.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 13, 2013
Previous Article:Savvis names Gery Messer as MD for Asia Pacific.
Next Article:KKR, Permira sell ProSiebenSat.1 stake at EUR31.53 p/s.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters